
-
Zentalis Pharmaceuticals NasdaqGM:ZNTL Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.
Location: 1359 Broadway, Suite 1710, New York, NY, 10018, United States | Website: https://zentalis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-200.4M
Cash
332.5M
Avg Qtr Burn
-37.88M
Short % of Float
12.36%
Insider Ownership
13.39%
Institutional Own.
80.35%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Azenosertib (ZN-c3) (oral inhibitor of WEE1) +/- niraparib Details Ovarian cancer, Cancer, PARPi Resistant Ovarian Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono Details Cyclin E1+ platinum-resistant ovarian cancer (PROC) | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Uterine disease, Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Cancer, Solid tumor/s | Phase 1b Data readout | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ multiple chemo Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer | Phase 1b Update | |
Azenosertib (ZN-c3) + gemcitabine Details Cancer, Osteosarcoma | Phase 1 Update | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Ovarian cancer, Cancer, Platinum Sensitive Ovarian Cancer | Phase 1 Update | |
Azenosertib (ZN-c3) + encorafenib and cetuximab Details Cancer, Metastatic colorectal cancer | Failed Discontinued | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) + azenosertib Details Acute myeloid leukemia, Cancer | Failed Discontinued | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Cancer, relapsed or refractory light chain amyloidosis | Failed Discontinued | |
ZN-c5 (Oral SERD) +Verzenio® (abemaciclib) Details Breast cancer, Cancer | Failed Discontinued | |
ZN-c5: Oral SERD (Monotherapy) Details Breast cancer, Cancer | Failed Discontinued |